MedPlus Health Services shares tumbled after the company reported a weaker-than-expected Q1FY27. Despite healthy 21.9% revenue growth to ₹1,880 crore, investors were disappointed by the profitability miss. Brokerage Nomura maintained its 'Buy' rating, highlighting MedPlus' long-term growth potential driven by its store expansion strategy.
from Economic Times https://ift.tt/yDn7Jih
from Economic Times https://ift.tt/yDn7Jih
MedPlus Health shares tumble 16% after Q1 profit falls 21% YoY. Should you buy, sell or hold?
Reviewed by News Today
on
July 22, 2026
Rating:
No comments: